Korean J Radiol.  2010 Dec;11(6):673-682. 10.3348/kjr.2010.11.6.673.

Evaluation of Porcine Pancreatic Islets Transplanted in the Kidney Capsules of Diabetic Mice Using a Clinically Approved Superparamagnetic Iron Oxide (SPIO) and a 1.5T MR Scanner

• Kim HS
• Kim H
• Park KS
• Moon WK

• KMID: 1119231
• DOI: http://doi.org/10.3348/kjr.2010.11.6.673

Abstract

OBJECTIVE
To evaluate transplanted porcine pancreatic islets in the kidney capsules of diabetic mice using a clinically approved superparamagnetic iron oxide (SPIO) and a 1.5T MR scanner.
MATERIALS AND METHODS
Various numbers of porcine pancreatic islets labeled with Resovist, a carboxydextran-coated SPIO, were transplanted into the kidney capsules of normal mice and imaged with a 3D FIESTA sequence using a 1.5T clinical MR scanner. Labeled (n = 3) and unlabeled (n = 2) islets were transplanted into the kidney capsules of streptozotocin-induced diabetic mice. Blood glucose levels and MR signal intensities were monitored for 30 days post-transplantation.
RESULTS
There were no significant differences in viability or insulin secretion between labeled and unlabeled islets. A strong correlation (r2 > 0.94) was evident between the number of transplanted islets and T2 relaxation times quantified by MRI. Transplantation with labeled or unlabeled islets helped restore normal sustained glucose levels in diabetic mice, and nephrectomies induced the recurrence of diabetes. The MR signal intensity of labeled pancreatic islets decreased by 80% over 30 days.
CONCLUSION
The transplantation of SPIO-labeled porcine islets into the kidney capsule of diabetic mice allows to restore normal glucose levels, and these islets can be visualized and quantified using a 1.5T clinical MR scanner.

Keyword

Porcine pancreatic islet; Superparamagnetic iron oxide; Magnetic resonance (MR); Diabetes; Xenotransplantation

MeSH Terms

Animals
Contrast Media/pharmacology
Dextrans/pharmacology
Diabetes Mellitus, Experimental/*therapy
Glucose Tolerance Test
*Islets of Langerhans Transplantation
Magnetic Resonance Imaging/*methods
Magnetite Nanoparticles
Mice
Microscopy, Electron
Statistics, Nonparametric
Swine

Figure

• 

  Fig. 1 Accumulation of superparamagnetic iron oxide in porcine islets. A. Graph shows dose-dependent increase of iron accumulation in islets labeled with Resovist. Islet cells labeled with Resovist (100 µg Fe/mL) were found to contain 13.2 ± 3.2 pg of total iron per cell, assuming that pancreatic islets contained 2000 cells on average. Values are expressed as means ± standard deviations of three independent experiments. Differences were considered significant at p values ≤ 0.05. *p ≤ 0.05 versus unlabeled. B. Prussian blue staining of labeled islets shows intracellular superparamagnetic iron oxide s (blue color) in all labeled islets. Islets were counterstained with nuclear fast red (red color). C. Transmission electron microscopy of labeled islets shows lysosome or endosome containing superparamagnetic iron oxides (arrows). G = dense granule, ISG = insulin secreting granule, M = mitochondria, N = nucleus

• 

  Fig. 2 Islet viability and insulin secretion. A. Viability of labeled and unlabeled islets determined using MTT assays were similar. B. Insulin secretion stimulated by treatment with glucose (3 mM or 16.7 mM) and theophylline (5 mM) showed no difference between labeled and unlabeled islets (p > 0.05). Values are expressed as means ± standard deviations of four independent experiments.

• 

  Fig. 3 In vitro MRI of superparamagnetic iron oxide-labeled porcine pancreatic islets. A. Gradient echo T2*-weighted images of 500 islets suspended in 1% agarose phantom show decreased signal intensity of labeled islets compared to unlabeled islets. B. T2 relaxation rates (1/T2) of labeled and unlabeled islets were 12.98 ± 0.01 sec-1 and 1.002 ± 0.24 sec-1, respectively (*p = 0.001). Islets were labeled for 48 hours in medium containing 100 µg Fe/mL of Resovist.

• 

  Fig. 4 MRI quantification of transplanted islets in normal mice. Different numbers (100, 250, 1000, and 2500) of porcine islets were transplanted into kidney capsules. A. Gradient echo T2*-weighted axial images show areas of hypointensity (arrows) in kidney capsules corresponding to different numbers of transplanted islets. B. Graph shows linear correlation (r2 = 0.9942) between transplanted islet number and graft volume as quantified on gradient echo T2*-weighted images. C. Graph shows linear correlation (r2 = 0.9356) between islet number and T2* relaxation time as measured on gradient echo T2*-weighted images.

• 

  Fig. 5 MRI and blood glucose changes in diabetic mice after transplantation of labeled and unlabeled islets. A. Gradient echo T2*-weighted coronal MR images show hypointense area (arrow in left panel) in left kidney containing 2500 transplanted, labeled islets. No signal drop is seen in kidney with unlabeled islets (arrow in right panel). B. Graph shows blood glucose levels in diabetic mice measured after labeled or unlabeled islet transplantation. Blood glucose levels in diabetic mice returned to normal (≤ 150 mg/dL) 24 hours after transplantation and remained normal for 30 days, but nephrectomy performed at 30 days post-transplantation caused recurrence of elevated blood glucose levels. C. Graph shows results of intraperitoneal glucose tolerance tests performed at 28 days post-transplantation. No significant differences were observed between labeled and unlabeled islets in terms of restoration of normal blood glucose levels. Values are expressed as mean ± standard deviation.

• 

  Fig. 6 Correlation between MR signal intensity changes and blood glucose levels in diabetic mice with labeled islets. A. Gradient echo T2*-weighted axial images show low signal intensity areas (arrows) in capsules of left kidneys of normoglycemic and hyperglycemic mouse at 8 and 25 days of post-transplantation. B. Blood glucose levels measured 25 days after transplantation of labeled islets in normoglycemic mice (n = 2) and hyperglycemic mouse (n = 1) were 120 ± 4.3 mg/dL and 308 mg/dL, respectively. C. Decreases in MRI signal intensities measured 25 days after transplantation of labeled islets in normoglycemic mice (n = 2) and hyperglycemic mouse (n = 1) were 81 ± 1.0% and 68%, respectively.

• 

  Fig. 7 Ex vivo MRI and histological analysis of diabetic mouse kidneys containing transplanted islets. A. Ex vivo MRI of kidneys excised 30 days after transplantation shows labeled pancreatic islets (arrow in upper panel) as hypointense areas. B. Prussian blue staining shows labeled pancreatic islets transplanted into kidney capsule (blue in upper panel). Insulin immunostaining shows well-preserved transplanted islets (brown in lower panel).

Reference

1. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000. 343:230–238.

2. Shapiro AM, Ricordi C, Hering B. Edmonton's islet success has indeed been replicated elsewhere. Lancet. 2003. 362:1242.

3. Kim SJ, Doudet DJ, Studenov AR, Nian C, Ruth TJ, Gambhir SS, et al. Quantitative micro positron emission tomography (PET) imaging for the in vivo determination of pancreatic islet graft survival. Nat Med. 2006. 12:1423–1428.

4. Evgenov NV, Medarova Z, Dai G, Bonner-Weir S, Moore A. In vivo imaging of islet transplantation. Nat Med. 2006. 12:144–148.

5. Elliott RB, Escobar L, Tan PL, Garkavenko O, Calafiore R, Basta P, et al. Intraperitoneal alginate-encapsulated neonatal porcine islets in a placebo-controlled study with 16 diabetic cynomolgus primates. Transplant Proc. 2005. 37:3505–3508.

6. Cozzi E, Bosio E. Islet xenotransplantation: current status of preclinical studies in the pig-to-nonhuman primate model. Curr Opin Organ Transplant. 2008. 13:155–158.

7. Moore A, Marecos E, Bogdanov A Jr, Weissleder R. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology. 2000. 214:568–574.

8. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT, et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol. 2000. 18:410–414.

9. Bulte JW, Zhang S, van Gelderen P, Herynek V, Jordan EK, Duncan ID, et al. Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination. Proc Natl Acad Sci U S A. 1999. 96:15256–15261.

10. Dodd CH, Hsu HC, Chu WJ, Yang P, Zhang HG, Mountz JD Jr, et al. Normal T-cell response and in vivo magnetic resonance imaging of T-cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles. J Immunol Methods. 2001. 256:89–105.

11. Dousset V, Delalande C, Ballarino L, Quesson B, Seilhan D, Coussemacq M, et al. In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance. Magn Reson Med. 1999. 41:329–333.

12. Jung SI, Kim SH, Kim HC, Son KR, Chung SY, Moon WK, et al. In vivo MR imaging of magnetically labeled mesenchymal stem cells in a rat model of renal ischemia. Korean J Radiol. 2009. 10:277–284.

13. Jirák D, Kríz J, Herynek V, Andersson B, Girman P, Burian M, et al. MRI of transplanted pancreatic islets. Magn Reson Med. 2004. 52:1228–1233.

14. Shapiro AM, Hao EG, Lakey JR, Yakimets WJ, Churchill TA, Mitlianga PG, et al. Novel approaches toward early diagnosis of islet allograft rejection. Transplantation. 2001. 71:1709–1718.

15. Evgenov NV, Medarova Z, Pratt J, Pantazopoulos P, Leyting S, Bonner-Weir S, et al. In vivo imaging of immune rejection in transplanted pancreatic islets. Diabetes. 2006. 55:2419–2428.

16. Tai JH, Foster P, Rosales A, Feng B, Hasilo C, Martinez V, et al. Imaging islets labeled with magnetic nanoparticles at 1.5 Tesla. Diabetes. 2006. 55:2931–2938.

17. Symonds P, Murray JC, Hunter AC, Debska G, Szewczyk A, Moghimi SM. Low and high molecular weight poly(L-lysine)s/poly(L-lysine)-DNA complexes initiate mitochondrial-mediated apoptosis differently. FEBS Lett. 2005. 579:6191–6198.

18. Kim HS, Choi Y, Song IC, Moon WK. Magnetic resonance imaging and biological properties of pancreatic islets labeled with iron oxide nanoparticles. NMR Biomed. 2009. 22:852–856.

19. Matuszewski L, Persigehl T, Wall A, Schwindt W, Tombach B, Fobker M, et al. Cell tagging with clinically approved iron oxides: feasibility and effect of lipofection, particle size, and surface coating on labeling efficiency. Radiology. 2005. 235:155–161.

20. Kim JH, Kim HI, Lee KW, Yu JE, Kim SH, Park HS, et al. Influence of strain and age differences on the yields of porcine islet isolation: extremely high islet yields from SPF CMS miniature pigs. Xenotransplantation. 2007. 14:60–66.

21. van der Burg MP, Basir I, Bouwman E. No porcine islet loss during density gradient purification in a novel iodixanol in University of Wisconsin solution. Transplant Proc. 1998. 30:362–363.

22. Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol. 2003. 13:1266–1276.

23. Berkova Z, Kriz J, Girman P, Zacharovova K, Koblas T, Dovolilova E, et al. Vitality of pancreatic islets labeled for magnetic resonance imaging with iron particles. Transplant Proc. 2005. 37:3496–3498.

24. Evgenov NV, Pratt J, Pantazopoulos P, Moore A. Effects of glucose toxicity and islet purity on in vivo magnetic resonance imaging of transplanted pancreatic islets. Transplantation. 2008. 85:1091–1098.

25. Jirak D, Kriz J, Strzelecki M, Yang J, Hasilo C, White DJ, et al. Monitoring the survival of islet transplants by MRI using a novel technique for their automated detection and quantification. MAGMA. 2009. 22:257–265.

26. Kriz J, Jirák D, Girman P, Berková Z, Zacharovova K, Honsova E, et al. Magnetic resonance imaging of pancreatic islets in tolerance and rejection. Transplantation. 2005. 80:1596–1603.